Asian Pacific journal of cancer prevention : APJCP · 2014
Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gunduz Seyda, Mutlu Hasan, Goksu Sema Sezgin, Arslan Deniz, Tatli Ali Murat, Uysal Mukremin, Coskun Hasan Senol, Bozcuk Hakan, Ozdogan Mustafa, Savas Burhan
Аннотация
BACKGROUND: Malignant mesothelioma (MM) is almost always fatal and few treatment options are available. The aim of this study was to evaluate the efficacy of oral cyclophosphamide and etoposide for patients who underwent standard treatment for advanced MM.
MATERIALS AND METHODS: This study included 22 malignant pleural mesothelioma patients who were treated with oral cyclophosphamide and etoposide (EE).
RESULTS: The average follow-up period of the patients was 39.1 months. Under the treatment of oral EE, median progression- free survival was 7.7 months [95%CI HR (4.3-11.1)] and median overall survival was 28.1 months [95%CI HR (5.8-50.3)]. The treatment response rates were as follows: 4 patients (27.3%) had a partial response (PR), 12 (54.5%) had stable disease (SD), and progressive disease (PD) was observed in 6 (35.9%).
CONCLUSIONS: Oral EE can be administered effectively to patients with inoperable malignant mesothelioma who had previously received standard treatments.
MATERIALS AND METHODS: This study included 22 malignant pleural mesothelioma patients who were treated with oral cyclophosphamide and etoposide (EE).
RESULTS: The average follow-up period of the patients was 39.1 months. Under the treatment of oral EE, median progression- free survival was 7.7 months [95%CI HR (4.3-11.1)] and median overall survival was 28.1 months [95%CI HR (5.8-50.3)]. The treatment response rates were as follows: 4 patients (27.3%) had a partial response (PR), 12 (54.5%) had stable disease (SD), and progressive disease (PD) was observed in 6 (35.9%).
CONCLUSIONS: Oral EE can be administered effectively to patients with inoperable malignant mesothelioma who had previously received standard treatments.